Madrigal Pharmaceuticals, Inc. Common Stock MDGL
i
Market dataready · fetched 2026-11-07T02:43:21.465Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-07T00:48:06.00375763Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-07T02:43:21.128140+00:00
Madrigal Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 450.63 | 61.9% | 13.0% | 362.85 | 70.5% | 11.7% |
| 25Δ | 438.93 | 58.0% | 10.4% | 372.57 | 67.7% | 9.8% |
| 30Δ | 431.43 | 57.8% | 9.0% | 379.45 | 69.9% | 8.7% |
| 35Δ | 424.03 | 55.9% | 7.6% | 386.64 | 70.2% | 7.6% |
| 40Δ | 417.55 | 55.4% | 6.5% | 393.74 | 70.5% | 6.7% |
| 45Δ | 412.14 | 57.2% | 5.8% | 400.76 | 71.1% | 5.8% |
| 50Δ | 406.52 | 57.4% | 5.0% | 407.96 | 72.0% | 5.0% |
| 55Δ | 400.77 | 56.4% | 4.2% | 415.33 | 72.3% | 4.3% |
| 60Δ | 395.48 | 54.6% | 3.4% | 423.05 | 72.6% | 3.6% |
| 65Δ | 390.25 | 52.6% | 2.7% | 431.61 | 73.8% | 3.0% |
| 70Δ | 384.30 | 53.2% | 2.3% | 442.02 | 76.7% | 2.5% |
| 75Δ | 378.48 | 53.2% | 1.8% | 454.79 | 80.2% | 2.0% |
| 80Δ | 373.09 | 51.0% | 1.3% | 473.60 | 87.5% | 1.6% |
20Δ
- Pseudo strike
- 450.63
- IV
- 61.9%
- B/E move
- 13.0%
- Pseudo strike
- 362.85
- IV
- 70.5%
- B/E move
- 11.7%
25Δ
- Pseudo strike
- 438.93
- IV
- 58.0%
- B/E move
- 10.4%
- Pseudo strike
- 372.57
- IV
- 67.7%
- B/E move
- 9.8%
30Δ
- Pseudo strike
- 431.43
- IV
- 57.8%
- B/E move
- 9.0%
- Pseudo strike
- 379.45
- IV
- 69.9%
- B/E move
- 8.7%
35Δ
- Pseudo strike
- 424.03
- IV
- 55.9%
- B/E move
- 7.6%
- Pseudo strike
- 386.64
- IV
- 70.2%
- B/E move
- 7.6%
40Δ
- Pseudo strike
- 417.55
- IV
- 55.4%
- B/E move
- 6.5%
- Pseudo strike
- 393.74
- IV
- 70.5%
- B/E move
- 6.7%
45Δ
- Pseudo strike
- 412.14
- IV
- 57.2%
- B/E move
- 5.8%
- Pseudo strike
- 400.76
- IV
- 71.1%
- B/E move
- 5.8%
50Δ
- Pseudo strike
- 406.52
- IV
- 57.4%
- B/E move
- 5.0%
- Pseudo strike
- 407.96
- IV
- 72.0%
- B/E move
- 5.0%
55Δ
- Pseudo strike
- 400.77
- IV
- 56.4%
- B/E move
- 4.2%
- Pseudo strike
- 415.33
- IV
- 72.3%
- B/E move
- 4.3%
60Δ
- Pseudo strike
- 395.48
- IV
- 54.6%
- B/E move
- 3.4%
- Pseudo strike
- 423.05
- IV
- 72.6%
- B/E move
- 3.6%
65Δ
- Pseudo strike
- 390.25
- IV
- 52.6%
- B/E move
- 2.7%
- Pseudo strike
- 431.61
- IV
- 73.8%
- B/E move
- 3.0%
70Δ
- Pseudo strike
- 384.30
- IV
- 53.2%
- B/E move
- 2.3%
- Pseudo strike
- 442.02
- IV
- 76.7%
- B/E move
- 2.5%
75Δ
- Pseudo strike
- 378.48
- IV
- 53.2%
- B/E move
- 1.8%
- Pseudo strike
- 454.79
- IV
- 80.2%
- B/E move
- 2.0%
80Δ
- Pseudo strike
- 373.09
- IV
- 51.0%
- B/E move
- 1.3%
- Pseudo strike
- 473.60
- IV
- 87.5%
- B/E move
- 1.6%
Options history
Table
| Date | IV (%) |
|---|---|
| 46.08% | |
| 43.95% | |
| 42.58% | |
| 43.62% | |
| 41.73% | |
| 44.07% | |
| 43.64% | |
| 43.79% | |
| 46.61% | |
| 45.46% | |
| 45.59% | |
| 46.21% | |
| 47.09% | |
| 46.73% | |
| 47.87% | |
| 48.82% | |
| 48.17% | |
| 45.73% | |
| 45.88% | |
| 45.87% | |
| 48.85% | |
| 46.86% | |
| 47.32% | |
| 47.32% | |
| 49.28% | |
| 49.95% | |
| 47.87% | |
| 51.23% | |
| 50.84% | |
| 51.26% | |
| 50.18% | |
| 48.79% | |
| 48.59% | |
| 47.59% | |
| 48.83% | |
| 49.56% | |
| 48.24% | |
| 48.33% | |
| 47.99% | |
| 49.03% | |
| 49.93% | |
| 48.84% | |
| 50.54% | |
| 49.89% | |
| 53.59% | |
| 54.52% | |
| 58.14% | |
| 60.11% | |
| 55.79% | |
| 56.62% | |
| 57.25% | |
| 57.76% | |
| 57.11% | |
| 58.39% | |
| 59.80% | |
| 59.80% | |
| 60.62% | |
| 61.41% | |
| 61.10% |
Biotechnology
MDWD
MediWound Ltd., a biopharmaceutical company, develops, manufactures and markets new and biotherapeutic solutions for tissue repair and regeneration. The company is headquartered…
More →MDXG
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia.
More →MESO
Mesoblast Limited, a biopharmaceutical company, develops and markets allogeneic cellular drugs. The company is headquartered in Melbourne, Australia.
More →MGNX
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. The company is headquartered in Rockville,…
More →MGTX
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focused on developing treatments for patients living with serious illnesses. The company is headquartered in New…
More →MIRM
Description unavailable
More →